Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Case-Based Guide to Clinical EndocrinologyPreface: Pituitary Tumors Are More Frequent Than Previously Thought

A Case-Based Guide to Clinical Endocrinology: Preface: Pituitary Tumors Are More Frequent Than... [The prevalence of clinically significant pituitary adenomas (PA) is increasing and now comprises approximately 16% of all primary cranial neoplasms. Prolactinomas (PRL-omas) and non-functioning pituitary adenomas (NFPA) are the most common PA types, followed by somatotroph (growth hormone; GH), corticotroph (adrenocorticotropic hormone; ACTH), and thyrotroph (thyroid stimulating hormone; TSH) adenomas. Frequently, treatment for functioning PA comprises surgery, medical therapy, and/or radiation. Several tumors are potentially more aggressive and require closer follow-up and/or multimodal therapy. Examples include sparsely granulated somatotroph adenoma, lactotroph adenoma in men, Crooke’s cell adenoma, silent corticotroph adenoma, and plurihormonal Pit-1-positive adenoma (previously called silent subtype III pituitary adenoma). New therapies for acromegaly and Cushing’s have been approved, and others are on the horizon in clinical trials.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

A Case-Based Guide to Clinical EndocrinologyPreface: Pituitary Tumors Are More Frequent Than Previously Thought

Editors: Davies, Terry F.
Fleseriu, Maria
A Case-Based Guide to Clinical Endocrinology — Jan 4, 2022
Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/a-case-based-guide-to-clinical-endocrinology-preface-pituitary-tumors-0T2hbrsla2
Publisher
Springer International Publishing
Copyright
© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022
ISBN
978-3-030-84366-3
Pages
3 –11
DOI
10.1007/978-3-030-84367-0_1
Publisher site
See Chapter on Publisher Site

Abstract

[The prevalence of clinically significant pituitary adenomas (PA) is increasing and now comprises approximately 16% of all primary cranial neoplasms. Prolactinomas (PRL-omas) and non-functioning pituitary adenomas (NFPA) are the most common PA types, followed by somatotroph (growth hormone; GH), corticotroph (adrenocorticotropic hormone; ACTH), and thyrotroph (thyroid stimulating hormone; TSH) adenomas. Frequently, treatment for functioning PA comprises surgery, medical therapy, and/or radiation. Several tumors are potentially more aggressive and require closer follow-up and/or multimodal therapy. Examples include sparsely granulated somatotroph adenoma, lactotroph adenoma in men, Crooke’s cell adenoma, silent corticotroph adenoma, and plurihormonal Pit-1-positive adenoma (previously called silent subtype III pituitary adenoma). New therapies for acromegaly and Cushing’s have been approved, and others are on the horizon in clinical trials.]

Published: Jan 4, 2022

Keywords: Pituitary adenoma; Pituitary tumors; Acromegaly; Cushing’s; Prolactinoma

There are no references for this article.